- Home
- ADAG
ADAG
Adagene Inc.
as of 08-21-2026 11:24am EST
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
| Founded: | 2011 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 260.3M | IPO Year: | 2020 |
| Target Price: | $8.25 | AVG Volume (30 days): | 290.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.44 - $4.85 | Next Earning Date: | 04-01-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered ADAG Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Adagene Inc. (ADAG)
Director
Avg Cost/Share
$3.75
Shares
2,000
Total Value
$7,500.00
Owned After
2,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| DO CUONG V | ADAG | Director | Aug 14, 2026 | Buy | $3.75 | 2,000 | $7,500.00 | 2,000 | |
| Luo Peter | ADAG | Chief Executive Officer | Aug 5, 2026 | Buy | $3.65 | 279 | $1,018.35 | 68,245 | |
| Luo Peter | ADAG | Chief Executive Officer | Aug 4, 2026 | Buy | $3.65 | 22,966 | $83,745.52 | 68,245 |
Compare ADAG vs Leading Stocks
See how ADAG stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ADAG Adagene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.